<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00759824</url>
  </required_header>
  <id_info>
    <org_study_id>01081</org_study_id>
    <nct_id>NCT00759824</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide</brief_title>
  <official_title>A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Lung Cancer Working Party</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Lung Cancer Working Party</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to determine if the addition of valproic acid to a
      combination of adriamycin, cyclophosphamide and vindesine could increase progression-free
      survival in patients relapsing after first-line chemotherapy including platinum derivatives,
      cisplatin or carboplatin, and etoposide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six-months progression-free survival</measure>
    <time_frame>The period between the day of registration and the date of first progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Survival will be dated from the date of registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every three cycles of chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>After each course of chemotherapy and at the end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy regimen (adriamycin, cyclophosphamide, vindesine) plus valproic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin, cyclophosphamide, vindesine, valproic acid</intervention_name>
    <description>Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of small-cell lung cancer (SCLC)

          -  SCLC refractory to prior chemotherapy regimen including platinum derivatives
             (cisplatin or carboplatin) and etoposide, either primary refractory (immediate
             progression or recurrence less than 3 months after the end of previous chemotherapy)
             or secondary refractory (sensitive patients to platinum plus etoposide in first-line,
             progressing or recurring less than 3 months after reintroduction of the same
             chemotherapy).

          -  At least one evaluable or measurable lesion

          -  Availability for participating in the detailed follow-up of the protocol

          -  Signed informed consent.

        Exclusion Criteria:

          -  Patient who were previously treated with anthracyclin or vinca-alcaloid derivatives or
             cyclophosphamide

          -  Performance status &lt; 60 on the Karnofsky scale

          -  A history of prior malignant tumour, except non-melanoma skin cancer or in situ
             carcinoma of the cervix or of the bladder or cured malignant tumour (more than 5-year
             disease free interval)

          -  A history of prior HIV infection

          -  Polynuclear cells &lt; 2,000/mm³

          -  Platelet cells &lt; 100,000/mm³

          -  Abnormal coagulation tests (aPTT, PTT, prothrombin time) and/or decreased fibrinogen

          -  Serum bilirubin &gt;1.5 mg/100 ml

          -  Transaminases more than twice the normal range

          -  Serum creatinine &gt; 1.5 mg/100 ml

          -  Recent myocardial infarction (less than 3 months prior to date of diagnosis)

          -  Congestive cardiac failure (ejection fraction of the left ventricle &lt; 50%) or
             uncontrolled cardiac arrhythmia

          -  Uncontrolled infectious disease

          -  Active epilepsy needing a specific treatment

          -  Concomitant treatment with IMAO, carbamazepine, mefloquine, phenobarbital, primidone,
             phenytoïn, lamotrigine, zidovudine

          -  Pregnancy or refusal to use active contraception

          -  A known allergy to valproic acid and/or doxorubicin, cyclophosphamide, vindesine

          -  Serious medical or psychological factors which may prevent adherence to the treatment
             schedule.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Berghmans, MD</last_name>
    <role>Study Chair</role>
    <affiliation>European Lung Cancer Working Party</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pneumology CHU Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pneumology Hôpital Saint-Joseph</name>
      <address>
        <city>Gilly</city>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pneumology Centre Hospitalier de Mouscron</name>
      <address>
        <city>Mouscron</city>
        <zip>7700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2008</study_first_submitted>
  <study_first_submitted_qc>September 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <last_update_submitted>February 11, 2015</last_update_submitted>
  <last_update_submitted_qc>February 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Small cell lung carcinoma</keyword>
  <keyword>Valproic acid</keyword>
  <keyword>Adriamycin</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Vindesine</keyword>
  <keyword>Second-line chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vindesine</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

